Why the study?
Vasovagal syncope is more prevalent in women with higher symptom burden and triggers, while treatment options can be limited in effectiveness.
This review outlines the distinct physiology, epidemiology, and presentation of vasovagal syncope in women, along with an overview of current and emerging treatment modalities.
Answers are grounded in this paper and cite their sources.
Raises awareness of sex-specific features in vasovagal syncope; leaves open optimal management strategies for women.
Vasovagal syncope (VVS) is the most common etiology of syncope affecting millions worldwide. VVS is significantly more prevalent in women who experience an overall higher symptom burden and experience a greater number of triggers and prodromal signs than men. Treatment options can be limited in their effectiveness The objectives of this review include describing the physiology, epidemiology, and presentation of VVS in women. Also, an up-to-date overview of available treatment modalities, including newer therapies for refractory VVS such as closed loop stimulation pacing and cardioneuroablation.
No takes yet. Share an insight, caveat, or question.
NEYMARK et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: